Previous issue | Volume 95 | ESPE2022 | Next issue

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

Card image cap
The 60th ESPE Annual Meeting will now be taking place in Rome, Italy.

Free Communications

Pituitary, Neuroendocrinology and Puberty

hrp0095fc9.1 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

COVID-19 and increased prevalence of female precocious puberty in Germany

Sonja Baehr , Dirk Schnabel , Joachim Woelfle , Felix Schreiner , Bettina Gohlke

Background: Several studies observed a positive secular trend for the occurrence of earlier puberty. Genetic background, weight gain, and environmental factors are assumed as contributors. In March 2020, WHO declared a worldwide pandemic of COVID-19. To reduce transmission, Germany and many other countries imposed regulations of social distancing and lockdowns leading to significant changes in daily life for children followed by an increase in obesity but also...

hrp0095fc9.2 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Can pre-treatment BMI influence long-term anthropometric and metabolic outcomes in girls with idiopathic central precocious puberty treated with GnRHa?

Bruzzi Patrizia , Sandoni Marcello , Valeri Lara , Trevisani Viola , Dalla Porta Francesca , Filomena Madeo Simona , Lucaccioni Laura , Predieri Barbara , Iughetti Lorenzo

Background: Gonadotropin releasing hormone analogs (GnRHa) are effective in improving adult height in children with precocious onset of puberty, rapid progression, and good growth potential. In last years, however, some transient metabolic complications have been described during the treatment without the reassurance of long-term data yet. The aim of our study is to clarify if body mass index (BMI) at diagnosis of idiopathic central precocious puberty (iCPP) c...

hrp0095fc9.3 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Therapeutic outcomes in gonadotropin-replaced males with congenital hypogonadotropic hypogonadism (CHH) with identified genetic variants

Rohayem Julia

Background: To delineate testicular responses to gonadotropin replacement in young males with genetically proven CHH.Patients and Methods: In n=72 young males with CHH and at least one variant detected within twenty-four investigated known CHH genes, gonadotropin replacement with hCG and rFSH s.c. was performed over a mean of 2±1 years. Bi-testicular volumes and serum Inhibin B served as baseline parameters, ...

hrp0095fc9.4 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Delayed puberty: unraveling the different trajectories and contributions of AI

Antoniou Maria-Christina , Xu Cheng , Zouaghi Yassine , Papadakis Georgios , Stoppa-Vaucher Sophie , Kolesinska Zofia , Bouthors Thérèse , Lore Ruiz Arana Inge , Elowe-Gruau Eglantine , Phan-Hug Franziska , Pasquier Jerôme , Adamo Michela , Deladoey Johnny , Vuissoz Jean-Marc , Busiah Kanetee , Hauschild Michael , Santoni Federico , Acierno James , Pitteloud Nelly

Introduction: Differentiation between constitutional delay of growth and puberty (CDGP) and congenital hypogonadotropic hypogonadism (CHH) during early adolescence is challenging, as patients exhibit a similar clinical picture and there are no definite clinical or biochemical markers that distinguish these 2 pathologies. A delay in diagnosis, especially for CHH, may have short and long-term health consequences. The aims of this study were: 1) To evaluate the u...

hrp0095fc9.5 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Gonadal Function, Pubertal Development, and Fertility Outcomes in Male and Female Survivors of Medulloblastoma - a Single Tertiary Centre Experience.

Stern Eve , Ben-Ami Michal , Gruber Noah , Yalon Michal , Abebe-Campino Gadi , Caspi Shani , Lurye Michal , Toren Amos , Modan-Moses Dalit

Background: Endocrine deficiencies, including impairment of the hypothalamic-pituitary-gonadal axis (HPGA), are found in the majority of survivors of medulloblastoma, due to high-dose craniospinal irradiation and gonadotoxic chemotherapy. Data regarding HPGA function in survivors of medulloblastoma is limited to small groups of patients and focusses mainly on female survivors. Furthermore, few studies investigated specific risk factors such as treatment protoc...

hrp0095fc9.6 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Cerebral infarction in childhood-onset craniopharyngioma patients: results of KRANIOPHARYNGEOM 2007

Boekhoff Svenja , Bison Brigitte , Genzel Daniela , Eveslage Maria , Friedrich Carsten , Flitsch Jörg , Müller Hermann L.

Background: Cerebral infarction (CI) is a known vascular complication following treatment of suprasellar tumors. The purpose of our study was to determine the incidence of cerebral infarction (CI) in a cohort of 244 German childhood-onset craniopharyngioma (CP) patients recruited between 2007 and 2019 with a high degree of completeness in the prospective, randomized trial KRANIOPHARYNGEOM 2007 (Clinical Trial No. NCT01272622). Up to now, risk factors for CI, i...